Determining the clinical outcomes, pharmacokinetics, and safety of remdesivir and GS-441524 in treating feline infectious peritonitis in domestic cats

Abstract

In the domain of feline medicine, feline infectious peritonitis (FIP) historically stood as a fatal coronavirus-driven disease. In one of the most rapidly evolving areas of feline medicine, remission and long-term survival are achievable in with new generation antiviral drugs. This thesis meticulously documents the prospective journeys of cats with FIP administered legally sourced remdesivir (RDV) with or without a transition to oral GS-441524. An overall survival statistic of 86% to 6 months was achieved, with the mean days to normalisation for key clinicopathologic signs associated with FIP also documented. Additionally, in vitro pharmacokinetics demonstrated RDV does not undergo conventional phase I-dependent hepatic metabolism in cats. The in vivo plasma pharmacokinetics of GS-441524 following intravenous administration of 15 mg/kg RDV are then described, with GS-441524 also documented to form within body cavity effusions and to be eliminated unchanged in urine in treated cats with FIP. This thesis contributes valuable evidence-based knowledge to support the use the safe and effective use of RDV and GS-441524 for treatment of FIP.